-- H:\DUK\9603PA3\IDS9a WP7.0

DEB/CAE/smm PDecember 30, 1998

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Jonathan S. Stamler and Andrew J. Gow

pplication No.: 08/796,164

Group Art Unit: 1654

Filed:

February 6, 1997

Examiner:

B. Celsa

Title:

MODIFIED HEMOGLOBINS, INCLUDING NITROSYLHEMOGLOBINS, AND USES THEREFOR

FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents

Washington, D.C. 20231

ν.	1	*	•
S	1	1	٠

[]

(Filed after payment of issue fee)

1 nis	information	Disclosure	Statement is	s submitted:

This l	Information Disclosure Statement is submitted:	
[]	under 37 CFR 1.129(a), or (First/Second submission after Final Rejection)	
[]	under 37 CFR 1.97(b), or (Within three months of filing national application; or date of entry of the national stage in international application; or before mailing merits; whichever occurs last)	date of first office action on the
[X]	under 37 CFR 1.97(c) together with either:	
	[] a Statement under 37 CFR 1.97(e), as checked below, or	8
	[X] a \$240.00 fee under 37 CFR 1.17(p), or (After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)	08796164 240.00
[]	under 37 CFR 1.97(d) together with: [] a Statement under 37 CFR 1.97(e), as checked below, and	00000247 08796164 24
	 [] a Petition under 37 CFR 1.97(d)(2), and [] a \$130.00 petition fee set forth in 37 CFR 1.17(i). 	1999 RTSEGAYE 126
[]	(Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee) Applicant requests that the attached IDS and cited reference(s)be placed in the appl	ication filewrapper.
	(Filed after payment of issue fee)	<u> </u>

PATENT APPLICATION

DOCKET NO.: DUK96r03pA3

Statement Under 37 CFR 1.97(e)

[]	Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or			
[]	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.			
N	o form	PTO-1449 is enclosed. See REMARKS below.			
[]	Copies of the cited references are enclosed.			
[]	Copies of cited references are enclosed except those entered in prior application, U.S. Serial No, and references that are not required to be submitted under 37 CFR 1.98.			
[]	The listed references were cited in the enclosed International Search Report in a counterpart foreign application.			
C	oncise	Explanation Requirement (non-English references):			
[]	The "concise explanation" requirement for reference(s) under 37 CFR 1.98(a)(3) is satisfied by:			
		[] the explanation provided on the attached sheet.			
		[] the explanation provided in the Specification.			
		[] submission of the enclosed International Search Report.			
		[] the enclosed English language abstract.			
	EMAR ovemb	Applicants respectfully request that the Examiner take note of Patent Application Number 08/559,172 filed on the er 13, 1995.			
It	is requ	sested that the information disclosed herein be made of record in this application.			
M	ethod	of payment:			
[]	Enclosed is a check in the amount of \$			
[]	Please charge Deposit Account 08-0380 in the amount of \$			
[·]	A copy of this Statement is enclosed.			
[X	(]	Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.			
		Respectfully submitted,			
		HAMILTON, BROOK, SMITH & REYNOLDS, P.C.			
		By <u>Carol A. Egner</u> Carol A. Egner			

Registration No.:38,866 Telephone: (781) 861-6240 Facsimile: (781) 861-9540

Lexington, Massachusetts 02421-4799 Dated: January 4, 1999